Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.

ABSTRACT:

SUBMITTER: Cai W 

PROVIDER: S-EPMC6788019 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature